Actos risk of cancer

31 May 2012 The diabetes drug Actos (pioglitazone) already carries a warning about its risk for bladder cancer, and now new research suggests that this risk 15 Jun 2011 FDA Drug Safety Communication: Update to ongoing safety review of Actos ( pioglitazone) and increased risk of bladder cancer

OBJECTIVE Some preclinical in vivo studies and limited human data suggest a possible increased risk of bladder cancer with pioglitazone therapy. This is an

Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study. Lewis JD(1), Ferrara A, Peng T, Hedderson 4 Sep 2014 Takeda has announced 10-year data from a longitudinal cohort study of its diabetes drug, pioglitazone (Actos), which it says illustrate there is 29 Aug 2014 ated no increased risk of bladder cancer, even with long-term use, the drug39s manufacturer said

Diabetes Drug Actos Again Linked to Bladder Cancer - WebMD

27 Aug 2014 In June 2011, the FDA warned Actos users of an increased risk of bladder cancer . Several recent studies have shown a much stronger link 31 May 2012 Main outcome measure Risk of incident bladder cancer associated with .. review of Actos (pioglitazone) and increased risk of bladder cancer

Pioglitazone and risk of bladder cancer: a meta-analysis of controlled studies. Ferwana M(1), Firwana B, Hasan R, Al-Mallah MH, Kim S, Montori VM, Murad MH 3 Jul 2012 The diabetes drug pioglitazone (Actos) appears to raise the risk of bladder cancer, but whether that is a class effect remains unclear,